EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia

Kainan Zhang, Xiaohang Ma, Xiaoxuan Lu, Guorui Ruan, Fangfang Wei, Hao Jiang, Yingjun Chang, Xiaojun Huang, Xiaosu Zhao

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06802-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Kainan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Insti…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Tandem Repeat Sequences. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Key Research and Development Program of China, 2023 Peking University People's Hospital Research and Development Fund Clinical Research Cultivation Project, CAMS Innovation Fund for Medical Science (CIFMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to investigate the prognostic value of FLT3-ITD molecular features such as allelic ratio (AR), variant allele frequency (VAF), insertion length, insertion number and insertion site in patients with de novo acute myeloid leukemia (AML). Next-generation sequencing (NGS) was used to detect FLT3-ITD mutations in 170 patients with newly diagnosed AML (except acute promyelocytic leukemia). FLT3-ITD patients with longer insertion lengths, higher allelic ratio, and more mutations had relatively shorter overall survival(OS), though not statistically significant. Early transplantation or FLT3 inhibitor therapy led to longer OS and event-free survival(EFS). Insertion sites located in Hinge Region(HR)/β1 domain and juxtamembrane domain (JMD) derived significantly greater benefit from early FLT3 inhibitor therapy(primarily sorafenib), showing significantly prolonged overall survival. HR/β1 insertion and multiple insertions showed a trend toward being risk factors for EFS. While white blood cell count > 30 × 10⁹/L and insertion of FLT3-ITD in the HR/β1 site were independent risk factors affecting patients' overall survival. Patients with high white blood cell counts and HR/β1 insertions demonstrated shorter overall survival, while early administration of FLT3 inhibitors resulted in significantly prolonged overall survival in this population. Early transplantation and FLT3 inhibitor therapy significantly improved prognosis in AML patients. In the era of FLT3-ITD targeted drug therapy combined with transplantation, the insertion site of FLT3-ITD based on high throughput sequencing results helps predict the efficacy of FLT3 inhibitors. Integrating white blood cell count with HR/β1 insertion site can identify a high-risk patient subgroup likely to benefit from FLT3 inhibitor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteTandem Repeat SequencesHumansRisk FactorsFemaleMaleMiddle AgedAdultMutationAgedPrognosisProtein Kinase InhibitorsSorafenibDisease-Free Survival

Stichwörter der Autor:innen

Acute myeloid leukemiaFLT3-ITDMolecularPrognosis

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanProtein Kinase InhibitorsSorafenib

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, No. 11 Xizhim…
  • Peking-Tsinghua Center for Life Sciences, Beijing, China.
  • Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.
  • Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China. zhao.xiaosu@outlook.com.
  • Collaborative Innovation Center of Hematology, Peking University, Beijing, China. zhao.xiaosu@outlook.com.

Förderung

  • The National Key Research and Development Program of China
  • 2023 Peking University People's Hospital Research and Development Fund Clinical Research Cultivation Project
  • CAMS Innovation Fund for Medical Science (CIFMS)

Zitieren

APA

Zhang, K., Ma, X., Lu, X., Ruan, G., Wei, F., Jiang, H., Chang, Y., Huang, X., & Zhao, X. (2026). Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-06802-x

Vancouver

Zhang K, Ma X, Lu X, Ruan G, Wei F, Jiang H, et al. Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia. Annals of Hematology. 2026. doi:10.1007/s00277-026-06802-x

BibTeX
@article{Zhang2026,
  author = {Zhang, Kainan and Ma, Xiaohang and Lu, Xiaoxuan and Ruan, Guorui and Wei, Fangfang and Jiang, Hao and Chang, Yingjun and Huang, Xiaojun and Zhao, Xiaosu},
  title = {Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06802-x}
}
Kostenlos starten →